Premium
Serum Mac‐2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia
Author(s) -
Peehl Donna M.,
Chen Zuxiong,
Nolley Rosalie
Publication year - 2010
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.21218
Subject(s) - medicine , prostate cancer , prostate , hyperplasia , prostatectomy , urology , pca3 , cancer , biopsy , prostate specific antigen , oncology
BACKGROUND Mac‐2 binding protein (Mac‐2BP) is a secreted protein that has been used as a serum prognostic marker for several types of cancers. A previous study showed that serum Mac‐2BP was significantly higher (∼2‐fold) in men with prostate cancer compared to healthy men. We investigated whether serum Mac‐2BP could distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia (BPH). METHODS A commercially available ELISA kit was used to measure Mac‐2BP in paired pre‐ and post‐prostatectomy sera from 10 men with high grade, large volume prostate cancer, in pre‐operative sera from 50 untreated men with high grade, large volume prostate cancer, and in sera from 50 men with clinical symptoms of BPH and biopsy‐negative for prostate cancer. Results were analyzed by Student's t ‐test and receiver operating characteristic (ROC) curves. RESULTS Levels of Mac‐2BP did not decrease in post‐prostatectomy sera, and Mac‐2BP values were not significantly different in the sera of men with prostate cancer versus those with BPH. CONCLUSION Serum Mac‐2BP does not appear to originate in the prostate and it is unlikely that Mac‐2BP can be used for the differential diagnosis of prostate cancer versus BPH. Prostate 71: 26–31, 2011. © 2010 Wiley‐Liss, Inc.